FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic ca
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.